EMA sticks to the recommendation of Astrazeneca's covid-vaccine
The EMA has announced that it sees a possible connection between Astrazeneca's Covid-19 vaccine and some highly rare cases of blood clots following vaccinations, but it maintains its recommendations to keep using the vaccine.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
The European Medicines Agency thinks that the advantages of the Astrazeneca vaccine against Covid-19 outweigh the disadvantages by far, states the agency at a press conference Wednesday afternoon.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Trust in Astrazeneca vaccine is dropping in Europe
For subscribers
.jpg&w=384&q=75)
